- Home
- PETS vs ANVS Comparison
PETS vs ANVS Comparison
Compare PETS & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | ANVS |
|---|---|---|
| Founded | 1996 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 69.1M |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PETS | ANVS |
|---|---|---|
| Price | $2.20 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 58.4K | ★ 923.2K |
| Earning Date | 06-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.92 | ★ 39.39 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $1.54 |
| 52 Week High | $4.32 | $5.50 |
Technical Indicators
Market Signals| Indicator | PETS | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 44.55 |
| Support Level | $2.19 | $1.86 |
| Resistance Level | $2.44 | $2.57 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 12.50 | 21.29 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.